Dr David Lau from the Ludwig Institute was awarded runner up for his concept entitled: “A phase II, single arm, multi-site study utilizing ctDNA to prospectively determine the evolution of cetuximab resistance prior to radiologic progression in metastatic colorectal cancer.”
